Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Haloperidol For Outpatient Symptom Management in Patients Diagnosed With Cannabinoid Hyperemesis Syndrome in the Emergrency Department

NCT07726069 is registered in ClinicalTrials.gov with University of Illinois at Chicago as lead sponsor.

NCT NCT07726069
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07726069 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Haloperidol For Outpatient Symptom Management in Patients Diagnosed With Cannabinoid Hyperemesis Syndrome in the Emergrency Department
Lead sponsor
University of Illinois at Chicago
Phase
Phase 1
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
January 31, 2028
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cannabinoid hyperemesis syndrome